Portal de Periódicos da CAPES

Surveillance of the Safety of Simultaneous Administration of Vaccines

1995; Wiley; Volume: 754; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1995.tb44464.x

1749-6632

Robert T. Chen, Penina Haber, John R. Mullen,

SARS-CoV-2 and COVID-19 Research

Annals of the New York Academy of SciencesVolume 754, Issue 1 p. 309-320 Surveillance of the Safety of Simultaneous Administration of Vaccines The Centers for Disease Control Prevention Experience ROBERT T. CHEN, Corresponding Author ROBERT T. CHEN Vaccine Safety and Development Activity (E61) National Immunization Program Centers for Disease Control and Prevention Atlanta, Georgia 30333To whom correspondence should be addressed.Search for more papers by this authorPENINA HABER, PENINA HABER Vaccine Safety and Development Activity (E61) National Immunization Program Centers for Disease Control and Prevention Atlanta, Georgia 30333Search for more papers by this authorJOHN R. MULLEN, JOHN R. MULLEN Vaccine Safety and Development Activity (E61) National Immunization Program Centers for Disease Control and Prevention Atlanta, Georgia 30333Search for more papers by this author ROBERT T. CHEN, Corresponding Author ROBERT T. CHEN Vaccine Safety and Development Activity (E61) National Immunization Program Centers for Disease Control and Prevention Atlanta, Georgia 30333To whom correspondence should be addressed.Search for more papers by this authorPENINA HABER, PENINA HABER Vaccine Safety and Development Activity (E61) National Immunization Program Centers for Disease Control and Prevention Atlanta, Georgia 30333Search for more papers by this authorJOHN R. MULLEN, JOHN R. MULLEN Vaccine Safety and Development Activity (E61) National Immunization Program Centers for Disease Control and Prevention Atlanta, Georgia 30333Search for more papers by this author First published: May 1995 https://doi.org/10.1111/j.1749-6632.1995.tb44464.xCitations: 9AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Parkman, P. D., H. E. Hopps, P. Albrecht & H. M. Meyer 1983. Imultaneous administration of vaccines. In Recent Advances in Immunization: A Bibliographic Review. N. A. Halsey & C. A. Quadros, Eds.: 65–80. Pan American Health Organization. Washington , DC . 2 V. S. Mitchell, N. M. Philipose & J. P. Sanford, Eds 1993. The Children's Vaccine Initiative: Achieving the Vision. National Academy Press. Washington , DC . 3 Clemens, J. D. & B. F. Stanton 1990. Long term evaluation of vaccine efficacy: Methodological issues for phase III and phase IV trials. In New Generation Vaccines. G. C. Woodrow & M. M. Levine, Eds.: 51–69. Marcel Dekker. New York , NY . 4 Deforest, A., S. S. Long, H. W. Lischner et al. 1988. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics 81: 237–246. 5 Black, S. B., H. R. Shinefield, D. Lampert et al. 1991. Safety and immunogencity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. Pediatr. Infect. Dis. J. 10: 92–96. 6 Miller, E., M. Goldacre, S. Pugh et al. 1993. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in U.K children. Lancet 341: 979–982. 7 Wassilak, S. G. F., J. W. Glasser, R. T. Chen et al. 1991. Design of a multicenter study of adverse events following vaccination in childhood. (Abstr.) J. Clin. Res. Pharmacoepidemiol. 5: 194. 8 CDC. 1989. Measles prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Wkly. Rep. 38(No. S-9): 1–18. 9 CDC. 1985. Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease. Morbid. Mortal. Wkly. Rep. 34: 201–205. 10 CDC. 1988. Update: Prevention of Haemophilus influenzae type b disease. Morbid. Mortal. Wkly. Rep. 37: 13–16. 11 CDC. 1991. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Wkly. Rep. 40(No. RR-1): 1–7. 12 Stetler, H. C., J. R. Mullen, J. P. Brennan, J. R. Livengood, W. A. Orenstein & A. R. Hinman 1987. Monitoring system for adverse events following immunization. Vaccine 5: 169–174. 13 Chen, R. T., S. C. Rastogi, J. R. Mullen et al. 1994. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12: 542–550. 14 National Center for Health Statistics. 1992. Public Use File Documentation. National Health Interview Survey of Child Health. 1991. (machine readable data file and documentation). National Center for Health Statistics. Hyattsville, MD. 15 C. P. Ghowson, C. J. Howe & H. V. FIneberg, Eds 1991. Adverse effects of pertussis and rubella vaccines: A report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. National Academy of Sciences. Washington , DC . Citing Literature Volume754, Issue1Combined Vaccines and Simultaneous Administration: Current Issues and PerspectivesMay 1995Pages 309-320 ReferencesRelatedInformation